Matrix

Yudo Bio provides biopharmaceutical products. It has its headquarters in Shanghai in China.

Yuan Yu Bio is a biotech firm that focused on the development of innovative microalgae biosynthesis technology.

Excell Biology is dedicated to addressing the biomedical industry's blockage and accomplishing the localization of essential raw materials. It offers customers biological medicine, cell, and gene therapy, and fundamental scientific research products and services of the quality and concentrates on three product sectors, including serum-free medium, fetal bovine serum, and identification reagents.

Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has unique advantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc.

Bota Biosciences (Bota Bio) is a global industrial biotechnology company connecting biological design to scale-up manufacturing to accelerate shifts to sustainable living. Bota has built an integrative bioengineering platform, to develop and implement efficient, eco-friendly, and cost-effective biomanufacturing technologies. Committed to its mission, Bota established its own pilot plant and manufacturing facility, affirming its dedication to offering scalable industrial solutions and market-ready products. This infrastructure strengthens support for customers and partners across industries such as nutrition, food, personal care, and animal health. Powered by a dynamic, multidisciplinary team, Bota Bio channels biotech innovations to create a global impact. The company's Series B financing has surpassed $100 million, bringing its aggregate funding to $145 million, with investment from notable strategic and financial investors, including Hong Shan Capital, Matrix Partners, and BASF Ventures.

Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has unique advantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc.

Senti Biosciences is a biotechnology company focused on synthetic biology and gene circuit engineering for therapeutic applications. Senti Bio utilizes a synthetic biology platform named Gene Circuits to develop therapies that offer improved precision and control. These circuits are engineered to selectively eliminate cancer cells while sparing healthy ones, enhancing specificity for target cells, and regulating drug expression post-administration.

D3 Bio is a biotechnology company that focuses on discovering and creating medications in oncology and immunology. The company combines clinical and market data to identify shortcomings in existing conventional medicines, employs unique drug development methodologies aimed at new disease targets and delivery routes, and provides patients with therapy alternatives in immunology and oncology.

Bota Biosciences (Bota Bio) is a global industrial biotechnology company connecting biological design to scale-up manufacturing to accelerate shifts to sustainable living. Bota has built an integrative bioengineering platform, to develop and implement efficient, eco-friendly, and cost-effective biomanufacturing technologies. Committed to its mission, Bota established its own pilot plant and manufacturing facility, affirming its dedication to offering scalable industrial solutions and market-ready products. This infrastructure strengthens support for customers and partners across industries such as nutrition, food, personal care, and animal health. Powered by a dynamic, multidisciplinary team, Bota Bio channels biotech innovations to create a global impact. The company's Series B financing has surpassed $100 million, bringing its aggregate funding to $145 million, with investment from notable strategic and financial investors, including Hong Shan Capital, Matrix Partners, and BASF Ventures.

Lumist is an integrated study app where learning starts with asking questions. With the snap of a picture, students can receive detailed step-by-step solutions for any academic question they have. The app also features a variety of livestream and pre-recorded teaching sessions to explain key concepts and prepare students for exams. Lumist is available for download on iOS and Android.

Lansion Biotechnology is specialized in research & development, production, sell, services of in vitro diagnostic reagents and devices. With its advanced technology concept, Lansionbio provides equioment, reagents and services to world-wild clients according to their needs.

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

Chameleon is changing the way they treat genetic diseases using gene therapy to deliver corrective genes using multiple systemic dose administrations. Research indicates that 20-30% of all infant fatalities are due to genetic disorders, and for those who survive, treatment options are often limited. Recent breakthroughs in gene therapy are saving lives, but there's still a long way to go. At Chameleon, their goal is to ensure every child can be treated with lower doses and accurate target specificity over time as their condition requires. They are committed to every child and family who suffers from a genetic disorder. Their mission is to make sure every Belle, Abby and Marian live to their 10th birthdays, learn to drive, go to prom and someday have healthy children of their very own.

SA Biotech is a Healthcare company.

Si'ao Biotechnology engages in the development and production of genetic engineering vaccines and test kits.

Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates in development.

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

23Mofang provides genetic testing services for Chinese people and conducts life data analysis business. The company relies on the Internet + genetic testing to build a large database of life, with the mission of "data life, benefit everyone", and build a trustworthy technology enterprise.